Rigicon

Rigicon is a privately held medical device company specializing in prosthetic urology, with a core focus on erectile dysfunction (ED) treatment. The company's primary commercial product is the Rigi10™, a next-generation malleable penile prosthesis featuring proprietary technologies like HydroShield™ coating and Flexible Rod Technology™. Rigicon operates globally from its headquarters in Ronkonkoma, New York, and positions itself as a scientific partner aiming to change the practice of prosthetic urology through innovation and a complete product portfolio. The company is in a revenue-generating, commercial stage, serving the urology surgical market.

Proprietary platform for malleable penile prostheses featuring Flexible Rod Technology™ (for bendability and natural feel), HydroShield™ hydrophilic coating (for easier implantation), a stainless-steel/titanium core (for rigidity), and patient-comfort design features.

The prosthetic urology market is a high-barrier, oligopolistic landscape dominated by two main players: Boston Scientific (following its acquisition of Mentor) and Coloplast. These companies have extensive product portfolios, long-term clinical data, and deep relationships with urologists. Rigicon competes as a smaller, innovative niche player, differentiating on specific technological features in malleable implants and potentially on price. Its success depends on carving out share through surgeon education and demonstrating superior product performance.